- The company was named to the list of BioSpace Movers and Shakers in July 2020 after veteran health plan executive Dennis A. Matheis joined its Board of Directors
- Global digital diabetes management market is projected to register CAGR of 17.8% by 2026
- DarioHealth’s platform lauded for centering on continual maximization of patient engagement
DarioHealth (NASDAQ: DRIO), a global digital therapeutics company serving its users with dynamic mobile health solutions, is in the spotlight as a major global player in the digital diabetes management market.
A recent report published by Data Bridge Market Research featured DarioHealth and its advancements in digital diabetes management – a growing global market expected to become the “next best thing” in the wake of the current coronavirus pandemic that has made it more difficult for diabetes patients to receive treatment. The market is projected to register a CAGR of 17.8 percent by 2026.
Digital diabetes management devices are used to self-monitor blood glucose levels. The technology combines diabetes monitoring hardware and mobile software with cloud computing infrastructure. Smart glucose monitors are wireless monitors that provide information about blood glucose data directly to your mobile device.
With 4.9 stars on the Apple App Store and 11,000 reviews, Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is a popular product with over 50,000 consumers around the globe. With a powerful commitment and contribution to chronic condition management through innovative digital therapeutic solutions, including a novel method for chronic disease data management, the company is rapidly moving toward addressing new chronic conditions and into new geographic markets.
The company was also named to the list of BioSpace Movers and Shakers in July 2020 after veteran health plan executive Dennis A. Matheis joined its Board of Directors on July 2, 2020 (http://ibn.fm/1BNMs).
Matheis brings to the DarioHealth Board nearly 30 years of experience leading regional and national health care plans and related organizations (http://ibn.fm/TIAVk). He currently serves as President of Optima Health, a division of Sentara Healthcare which has more than 850,000 members and a network of over 26,000 providers.
“Over the course of my health care career, I have seen first-hand how even modest behavior changes can positively impact the long-term health of people suffering from costly and in some cases debilitating chronic medical conditions,” stated Matheis. “I have been aware of Dario for some time now, and I believe the company’s highly engaging user platform sets the company apart and provides tangible results for patients and demonstrated savings for payers.”
According to CEO Erez Raphael, Matheis will leverage his experience to aid DarioHealth in its transition to a business-to-business-to-consumer model, serving people suffering from chronic diseases via direct relationships with health plans, large employers, and benefits administrators.
The company was also cited in a recent article about patient engagement that emphasizes Dario platform’s continual maximization of patient engagement through personalization, including “nudges” and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices (http://ibn.fm/vrw22).
The report further underlines that health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs that encourage patients to be more involved in managing their conditions, and proactively take preventative measures that reduce risk, emergency room visits, and preventable hospitalization.
With personalized, mobile health solutions, DarioHealth provides more control and greater independence for people with chronic conditions as they work to manage their daily challenges, empowering individuals to make healthy adjustments to their lifestyle choices and improve their overall health.
For more information, visit the company’s website at www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
